H.C. Wainwright Reiterates Buy Ratings for IREN and Roivant Sciences

Investment firm H.C. Wainwright has maintained its buy recommendations for both IREN and Roivant Sciences, highlighting strong growth prospects driven by artificial intelligence revenue and clinical developments. The upgrades reflect analyst confidence in the companies' near-term performance.